SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-034342
Filing Date
2023-03-20
Accepted
2023-03-20 12:11:15
Documents
12
Period of Report
2023-03-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2310020d1_8k.htm   iXBRL 8-K 34060
  Complete submission text file 0001104659-23-034342.txt   209018

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA acur-20230320.xsd EX-101.SCH 3040
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE acur-20230320_lab.xml EX-101.LAB 34477
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acur-20230320_pre.xml EX-101.PRE 22600
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2310020d1_8k_htm.xml XML 3502
Mailing Address 616 N. NORTH COURT, SUITE 120 . PALATINE IL 60067
Business Address 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 847-705-7709
ACURA PHARMACEUTICALS, INC (Filer) CIK: 0000786947 (see all company filings)

IRS No.: 110853640 | State of Incorp.: NY | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-10113 | Film No.: 23745426
SIC: 2834 Pharmaceutical Preparations